Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Trial Details
NCT Number NCT06927466
Lead Sponsor Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Conditions Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment 33 participants
Start Date 2024-09-19
Primary Completion 2026-01-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-22